Knee osteoarthritis
Conditions
Interventions
Control Group/Simple Meniscus Injury Group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for the KOA Group: (1) Age >= 40 years, any gender. (2) Meeting the clinical diagnostic criteria for knee osteoarthritis, presenting with typical symptoms and signs (e.g., knee pain, stiffness, limited mobility), supported by imaging evidence. (3) Imaging findings indicative of knee osteoarthritis changes, with a Kellgren-Lawrence (K-L) grade >= 2, or clear evidence of cartilage degeneration/osteophyte formation. (4) Undergoing surgical treatment for KOA, such as arthroscopic debridement, osteotomy, or joint replacement, during which sufficient synovial tissue can be obtained. (5) No recent acute systemic infection or other severe systemic diseases affecting the inflammatory state of the joint. Inclusion Criteria for the Control Group (Simple Meniscus Injury): (1) Age 18–60 years, any gender. (2) Clinically and radiologically confirmed diagnosis of meniscus injury, scheduled for arthroscopic surgery due to definitive symptoms. (3) No imaging evidence of osteoarthritis or only minimal degenerative changes in the knee joint: K-L grade 0–1, with cartilage degeneration, if present, not exceeding a mild range. (4) No history of systemic diseases associated with definite synovitis, and sufficient synovial tissue can be obtained during the surgery.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for the KOA Group: (1) Complicated by other types of arthritis or immune system diseases: rheumatoid arthritis, ankylosing spondylitis, gout/pseudogout, psoriatic arthritis, systemic lupus erythematosus, etc. (2) Evidence of significant infectious arthritis in the knee joint or severe systemic infection within the last 3 months. (3) Receipt of treatments within the last 3 months that may significantly affect synovial inflammation and gene expression, including intra-articular injections of glucocorticoids, PRP, or hyaluronic acid; systemic glucocorticoid or immunosuppressant therapy; anti-tumor chemotherapy/radiotherapy, etc. (4) History of severe knee joint trauma (e.g., fractures, short-term post-ligament reconstruction surgery) or recent major surgery affecting local tissue inflammatory response. (5) Complicated by tumors, severe hepatic or renal dysfunction, severe cardiopulmonary dysfunction, or other conditions that may affect the overall inflammatory state or surgical safety. Exclusion Criteria for the Control Group (Simple Meniscus Injury): (1) Any definitive or suspected evidence of osteoarthritis, inflammatory joint disease, or crystal-associated arthropathy. (2) Complicated by complex injuries requiring reconstruction of major knee ligaments (e.g., ACL/PCL reconstruction), obvious extensive cartilage defects, or severe bone contusions, to avoid introducing a "degeneration/inflammation background" into the control group. (3) History of intra-articular injections, systemic glucocorticoid/immunosuppressant use, or other treatments significantly affecting synovial inflammation within the last 3 months. (4) Previous history of knee joint infection, tuberculosis, or tumor, or recent severe systemic infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression levels of genes related to dimer activity and leptin; | — |
Countries
China
Contacts
Public ContactJiaxin Zhang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed